| Study Period | 2023 - 2030 |
| Market Size (2025) | USD 649.92 Million |
| Market Size (2030) | USD 948.77 Million |
| CAGR (2025 - 2030) | 7.86 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Biomarker Testing Services Market Analysis
The Biomarker Testing Services Market size is estimated at USD 649.92 million in 2025, and is expected to reach USD 948.77 million by 2030, at a CAGR of 7.86% during the forecast period (2025-2030).
The growth of the biomarkers testing services market can be attributed to factors such as rising demand for personalized medicine, the increasing prevalence of chronic diseases, and the heightened need for biomarkers in drug development and clinical trials.
As global neurological diseases become more common, the adoption of biomarkers is likely to intensify. For instance, a study of the Global Burden of Disease (GBD), published by the World Federation of Neurology in October 2023, stated that the number of people living with brain disease is expected to double by 2050. The study also highlighted that over 40% of the global population currently suffers from some kind of neurological condition. Additionally, in April 2024, Neurology Journals published a study projecting approximately 4.9 billion brain disorder cases by 2050, marking a 22% rise from the last three-year estimates. Such an increase in the prevalence of neurological diseases will likely push companies to develop newer targets for cancer diagnosis, ultimately boosting the demand for biomarker testing services over the coming years.
Moreover, increasing research and development activities by several market players is a major contributor to market growth. For instance, in November 2023, Charles River Laboratories entered into a partnership agreement with Aitia, Inc.to incorporate Logica, an innovative platform, into their discovery programs focused on oncology and neurodegenerative diseases. This collaboration aims to leverage Logica's capabilities in biomarker identification and validation, thereby enhancing the efficacy of drug discovery efforts. The integration is expected to drive advancements in biomarker testing services within the biopharmaceutical industry.
Thus, owing to the above-mentioned factors, such as the rising prevalence of life-threatening diseases, the rising usage of biomarkers in disease diagnosis, and increasing research and development activities. the market is expected to grow over the forecast period. However, issues related to regulatory and reimbursement systems and the high cost of biomarkers may hinder the market's growth.
Biomarker Testing Services Market Trends
The Biomarker Assay Development & Validation Segment is Expected to Hold a Major Share in the Biomarker Testing Services Market during the Forecast Period
Factors such as the potential role of biomarker assay development and validation in clinical research, rising demand for new drug development, and the growing demand for personalized medicine solutions are likely to drive the biomarker assay development & validation segment growth in the biomarker testing services market. Moreover, the growing prevalence of chronic diseases like cancer, cardiovascular disorders, and diabetes fuels the demand for biomarker assays for early detection, diagnosis, and monitoring of these conditions.
Biomarker assay development services play a critical role in enabling early disease detection and personalized treatment strategies. For instance, in October 2024, Adx Neurosciences partnered with Alamar Biosciences, a company specializing in biomarker assays for neurodegenerative diseases. Together, they aimed to develop tailored assays for detecting and quantifying blood biomarkers, facilitating the progression of novel treatments for neurodegenerative conditions, notably Parkinson's disease. Companies are strategically collaborating to advance the development of biomarkers, aiming to create more effective therapies, which in turn is anticipated to boost the segment growth.
Additionally, strategic initiatives backed by pharma companies to roll out the importance of biomarker testing also drives the demand for biomarker assay development and validation services. For instance, in February 2024, Amgen Inc. and Astellas Pharma launched an awareness campaign called Test Your Biomarkers. This new education and awareness campaign was specifically aimed at patients and their caregivers about the importance of testing for stomach cancer markers. The campaign raised awareness among patients and caregivers about the significance of biomarker testing for stomach cancer. This heightened awareness is likely to increase demand for biomarker assays that specifically target stomach cancer markers. This is further expected to drive the need for specialized assay development and validation services in this area.
Thus, strategic collaboration to develop novel biomarkers, and rising awareness about the importance of biomarker in cancer diagnostics are some factors that drive the segment growth during the forecast period.
Understand The Key Trends Shaping This Market
Download PDF
North America is Expected to Hold a Significant Share in the Market
North America is expected to dominate the biomarker testing services market. This dominance can be attributed to a supportive regulatory environment, a strong presence of leading market players, and ongoing technological innovations.
Moreover, contributing factors include favorable government support, an uptick in laboratory diagnostic testing driven by a rising chronic disease burden, and heightened R&D investments from public organizations, which are likely to drive the market in the North American region during the forecast period. For instance, in October 2024, the Advanced Research Projects Agency for Health, an agency within the United States Department of Health and Human Services, launched a program to develop a tear-based biomarker measurement platform. The platform aims to provide continuous health monitoring and ultra-precise medication dosing for personalized treatment. Introducing new technologies often drives market growth, creating demand for related biomarker testing services and applications.
Moreover, the high burden of chronic disease across North America is expected to bolster the market’s growth over the forecast period. For instance, in 2023, the Canadian Cancer Society (CCS) reported a rising trend in cancer diagnosis in Canada, highlighting the disease's significant toll on the nation's healthcare. As per the same source mentioned above, in 2023, 124,200 men and 114,900 women were diagnosed with cancer. As biomarkers have broad applications in diagnosing and treating cancer, the demand for biomarket testing services is expected to increase in the country.
Thus, owing to the factors mentioned above, such as increase in research and development activities, favorable government support, rising burden of chronic disease that leads to the development of biomarkers, the biomarkers market is expected to show lucrative growth in North America over the forecast period.
Get Analysis on Important Geographic Markets
Download PDF
Biomarker Testing Services Industry Overview
The biomarker testing services market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Each entity contributes to this fragmentation through unique innovations, regional launches, partnerships with diverse organizations, and promotions across various leading platforms. Some of the key players operating in the market are Charles River Laboratories, Svar Life Science, ICON Plc, Eurofins Scientific, IQVIA, Frontage Labs, and Syneos Health, among others.
Biomarker Testing Services Market Leaders
-
Charles River Laboratories
-
ICON Plc
-
Eurofins Scientific
-
IQVIA
-
Syneos Health
- *Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competiters?
Download PDF
Biomarker Testing Services Market News
- July 2024: Progentec Diagnostics launched its proprietary biomarker blood tests, designed for the proactive management of systemic lupus erythematosus. Developed in collaboration with Mayo Clinic Laboratories, the AiSLE DX lupus disease activity index and AiSLE DX lupus flare risk index tests are now readily available to all clients of Mayo Clinic Labs.
- January 2024: Tempus, a frontrunner in artificial intelligence and precision medicine, has expanded its collaboration with AstraZeneca. This partnership utilizes Tempus Next, an AI-enabled care platform that enables physicians to deliver the next step in a patient's care journey with technology to enhance guideline-directed biomarker testing for patients with non-small cell lung cancer.
Biomarker Testing Services Industry Segmentation
As per the scope of the report, biomarker testing involves the identification, measurement, and analysis of specific biological markers that indicate normal or abnormal biological processes, disease presence, or response to treatment.
The biomarker testing services market is segmented by services, applications, end users, and geography. In terms of services, the market is segmented as biomarker assay development & validation, biomarker identification, biomarker profiling, and others. The other types of services include the development of drug-specific pharmacodynamic markers, and sample analysis, among others. By application, the market is segmented into disease diagnosis, drug development, clinical trials, and others. The other applications include toxicology and safety monitoring, and disease management. By end user, the market is segmented as pharmaceutical and biotechnology companies, academic institutes, and research centers, and others. The other end-users include diagnostic laboratories and contract research organizations, among others. By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. For each segment, the market sizing and forecasts have been done on the basis of value (in USD)
| By Service Type | Biomarker Assay Development & Validation | ||
| Biomarker Idendification | |||
| Biomarket Profilling | |||
| Others | |||
| By Application | Disease Diagnosis | ||
| Drug Development and Clinical Trials | |||
| Others | |||
| By End User | Pharmaceutical and Biotecnology Companies | ||
| Academic Institutes and Research Centers | |||
| Others | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
Need A Different Region or Segment?
Customize Now
Biomarker Testing Services Market Research FAQs
How big is the Biomarker Testing Services Market?
The Biomarker Testing Services Market size is expected to reach USD 649.92 million in 2025 and grow at a CAGR of 7.86% to reach USD 948.77 million by 2030.
What is the current Biomarker Testing Services Market size?
In 2025, the Biomarker Testing Services Market size is expected to reach USD 649.92 million.
Who are the key players in Biomarker Testing Services Market?
Charles River Laboratories, ICON Plc, Eurofins Scientific, IQVIA and Syneos Health are the major companies operating in the Biomarker Testing Services Market.
Which is the fastest growing region in Biomarker Testing Services Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Biomarker Testing Services Market?
In 2025, the North America accounts for the largest market share in Biomarker Testing Services Market.
What years does this Biomarker Testing Services Market cover, and what was the market size in 2024?
In 2024, the Biomarker Testing Services Market size was estimated at USD 598.84 million. The report covers the Biomarker Testing Services Market historical market size for years: 2023 and 2024. The report also forecasts the Biomarker Testing Services Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Biomarker Testing Services Industry Report
Statistics for the 2025 Biomarker Testing Services market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Biomarker Testing Services analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
